Evidence map›Paper›PMID 38201381›Full record

ArticleDiagnostics (Basel, Switzerland)2023

"

Agnes Nakyanzi, Faith Naddunga, Michelle A Bulterys, Andrew Mujugira, Monique A Wyatt, Brenda Kamusiime, Alisaati Nalumansi, Vicent Kasiita, Sue Peacock, Connie L Celum and 1 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Agnes NakyanziInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Faith NaddungaInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Michelle A BulterysDepartment of Global Health, University of Washington, Seattle, WA 98109, USA.ORCID 0000-0001-9403-5084
Andrew MujugiraInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Monique A WyattDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA.
Brenda KamusiimeInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Alisaati NalumansiInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Vicent KasiitaInfectious Diseases Institute, Makerere University, Kampala P.O. Box 7072, Uganda.
Sue PeacockDepartment of Global Health, University of Washington, Seattle, WA 98109, USA.
Connie L CelumDepartment of Global Health, University of Washington, Seattle, WA 98109, USA.
Norma C WareDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA.
Infectious Diseases Institute · UGUniversity of Washington · USBrigham and Women's Hospital · USHarvard University · US

Funding

VENEREAL DISEASET32AI007140 · NIAID · UNIVERSITY OF WASHINGTON · PI Julia Cook Dombrowski · 1985 to 2026
$19.4M
HIV self-testing and PrEP to increase testing and prevention uptake among male partners and improve postpartum ART use in PMTCT B+ programs in UgandaR01MH113434 · NIMH · UNIVERSITY OF WASHINGTON · PI CELUM, CONNIE L · 2017 to 2021
$3.4M
NIAID NIH HHS T32 AI007140NIMH NIH HHS NIMH R01 MH113434NIMH NIH HHS R01 MH113434
6 · The paper itself

Abstract

backgroundHigh adherence to antiretroviral therapy (ART) is critical for achieving viral suppression and preventing onward HIV transmission. ART continuation can be challenging for pregnant women living with HIV (PWLHIV), which has critical implications for risk of vertical HIV transmission. Point-of-care viral load (POC VL) testing has been associated with improved treatment and retention outcomes. We sought to explore acceptability of POC VL testing among Ugandan PWLHIV during pregnancy and postpartum.

methodsThis multimethod analysis drew on quantitative and qualitative data collected between February and December 2021. Quantitatively, we used an intent-to-treat analysis to assess whether randomization to clinic-based POC VL testing during pregnancy and infant testing at delivery was associated with improved viral suppression (≤50 copies/mL) by 3 months postpartum compared to standard-of-care (SOC) VL testing through a central laboratory, adjusting for factorial randomization for the male partner testing strategy. Additionally, a subset of 22 PWLHIV in the POC VL arm participated in in-depth qualitative interviews. We inductively analyzed transcripts to develop categories representing concepts that characterized women's perceptions of POC VL testing during pregnancy and at delivery and ways that POC VL testing may have impacted their ART adherence and viral suppression. Key themes around women's perceptions of POC VL testing were then organized into main categories.

resultsOverall, 151 PWLHIV were enrolled into the study, 77 (51%) of whom were randomized to receive POC VL testing during pregnancy and at delivery. Women reported in qualitative interviews that POC VL testing had (1) motivated their ART adherence during pregnancy and postpartum and that they felt this testing method had (2) helped them protect their infants from acquiring HIV and (3) improved their emotional wellbeing.

conclusionsPOC VL testing was highly acceptable among Ugandan PWLHIV and was viewed as an important tool that women believed improved their ART adherence, gave them information necessary to protect their infants from vertical HIV acquisition, and improved their emotional wellbeing. These findings support the global scale-up of POC VL testing in settings with high HIV burden, especially for PWLHIV who may be at risk of treatment disruptions or loss to follow-up.

Indexed as

ART adherencePMTCTPOC VLpoint-of-care viral load testingviral load

Identifiers

PMID38201381
PMCPMC10795616
OpenAlexW4390339440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.